Secondary Prevention in Patients With ACS and Diabetes:

How Can We Optimize Therapy?

Panelists

Learning Objectives

Learning Objectives

Diabetes as a CV Risk Factor

Impact of Gluco-Metabolic Characteristics on Risk of Major

Cardiovascular Events

Risk Factors in Patients With T2D After ACS

The HDL Hypothesis

Meta-analysis of Intensive Statin Trials:

Coronary Death or Myocardial Infarction

Intensive Glucose Control in Critically Ill Patients: Death From

Any Cause

UKPDS: Extended Follow-up Benefits of Glycemic Control

Comparison of CETP Inhibitors

DAL-OUTCOMES: 3 Years

AIM-HIGH: End Point at 36-month Follow-up

ACCORD Lipid: Hazard Ratios for the Primary Outcome

SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in

T2D

AleCardio: Aleglitazar in Patients With T2D and ACS

Unmet Needs: Diabetes in Post-ACS Patients

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)